Orthopedic Regenerative Medicine Market Is Growing Rapidly With Eli Lily And Company Acquiring Prevail Therapeutics Including Clinical Program PR001, An Experimental Gene-Therapy For Neuronopathic Gaucher Disease
Orthopedic regenerative medicine is a rapidly expanding area of medical science. As medical science continues to discover new and effective ways to deliver treatments to patients, it is often changing the way we do surgery. For example, researchers have learned that by using stem cells in anti-inflammatory arthritis clinical trials, the pain experienced by some patients can be greatly reduced. Stem cells are also being used for the direct delivery of anti-inflammatory proteins in cartilage repair and tissue regeneration. These types of treatments hold great promise for treating a wide variety of ailments.
Rising prevalence of chronic diseases
such as osteoarthritis and tendon, ligament, and cartilage injuries is expected
to drive growth of the global orthopedic regenerative medicine market. According
to the Centers for Disease Control and Prevention (CDC), osteoarthritis affects
over 32.5 million U.S. adults. According to the global burden of disease study,
around 10 to 15% of all adults aged 60 years and above suffer from some degree
of osteoarthritis. Orthopedic regenerative medicines are typically helpful in
the treatment of osteoarthritis and ligament injuries. Furthermore,
regenerative medicines boost the body’s ability to use its repair systems to
heal diseased or damaged cells due to arthritis. Hence, these factors are
expected to drive growth of the global orthopedic regenerative medicine market.
Furthermore, growing investments in regenerative medicine research and rising
pipeline of regenerative medicine products are expected to propel the global
orthopedic regenerative medicine market growth in the near future.
However, ethical concerns regarding
the use of embryonic stem cells in R&D and high cost of gene therapies is
expected to restrain growth of the global orthopedic regenerative medicine
market. Besides, increasing demand for organ transplantations can present
lucrative growth opportunities. Among regions, North America is expected to
witness significant growth in the global orthopedic regenerative medicine
market. This is owing to rising geriatric population suffering from
osteoarthritis and the robust presence of major research organizations.
Furthermore, Asia Pacific is expected to register a robust growth rate, owing
to developing healthcare infrastructure in the region.
Key companies involved in the global
orthopedic regenerative medicine market are AstraZeneca, Merck & Co., Inc.,
F Hoffmann-La Roche Ltd., Eli Lilly and Company, Pfizer Inc., Integra LifeSciences Corporation, and Baxter International.
For instance, in December 2021, Eli
Lily and Company acquired Prevail Therapeutics including clinical program
PR001, an experimental gene-therapy for neuronopathic Gaucher Disease.
Comments
Post a Comment